Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Leukemia

 

CPX-351 Versus 7+3 for Older Patients (2651)
Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age with Untreated High Risk (Secondary) AML

Investigator: John Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01696084

GS-1101 (CAL-101) for Previously Treated Chronic Lymphocytic Leukemia (FH 2693)
A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

Investigator: John M. Pagel, MD;   Conditions: Chronic Lymphocytic Leukemia;    Status: Pending;   Study ID: NCT01659021

PCI-32765 Versus Chlorambucil Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (FH 2716)
A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2)

Investigator: John M. Pagel, MD;   Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma;    Status: Pending;   Study ID: NCT01722487

Extension Study for Patients Who Participated in Study PCYC-1115-CA (FH 2717)
An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil)

Investigator: John M. Pagel, MD;   Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma;    Status: Pending;   Study ID: NCT01724346

Combination Chemotherapy for Young Patients With Newly Diagnosed T-Cell ALL (COG AALL0434)
Intensified Methotrexate, Nelarabine (Compound 506U78 IND # 52611) and Augmented BFM Therapy in Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia

Investigator: Blythe Thomson, MD;   Conditions: Acute Lymphoid Leukemia (ALL);    Status: Recruiting;   Study ID: NCT00408005

TRU-016 + Bendamustine vs. Bendamustine Alone for CLL (FH 2441)
A Phase 1b/2 Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination with Bendamustine vs. Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia

Investigator: John Pagel, MD, PhD;   Conditions: Chronic Lymphocytic Leukemia (CLL);    Status: Recruiting;   Study ID: NCT01188681

GS-1101 for Previously Treated Chronic Lymphocytic Leukemia (FH 2613)
A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent GS 1101 (CAL 101) as Therapy for Patients With Previously Treated Chronic Lymphocytic Leukemia

Investigator: John M. Pagel, MD;   Conditions: Chronic Lymphocytic Leukemia;    Status: Recruiting;   Study ID: NCT01539291

GS-1101 With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (FH 2612)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS 1101 (CAL-101) in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia

Investigator: John M. Pagel, MD;   Conditions: Chronic Lymphocytic Leukemia;    Status: Pending;   Study ID: NCT01539512

AC220 Post Transplant for Acute Myeloid Leukemia (2487)
A Phase 1 Study of AC220 (ASP2689) as Maintenance Therapy in Subjects With Acute Myeloid Leukemia Who Have Been Treated With an Allogeneic Hematopoietic Stem Cell Transplant

Investigator: Brenda Sandmaier, MD;   Conditions: Acute Myeloid Leukemia (AML);    Status: Recruiting;   Study ID: NCT01468467

GS-1101 With Bendamustine and Rituximab for Chronic Lymphocytic Leukemia (FH 2597)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia

Investigator: John M. Pagel, MD;   Conditions: Chronic Lymphocytic Leukemia;    Status: Recruiting;   Study ID: NCT01569295

Vorinostat + Chemotherapy for CLL or SLL (PSOC-2401)
A Phase I/II Study of Fludarabine (F), Cyclophosphamide ©), Rituximab ®), and Vorinostat (V) Followed by RV Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small LymphoCtic Lymphoma (SLL)

Investigator: John Pagel, MD, PhD;   Conditions: Leukemia, Lymphoma;    Status: Recruiting;   Study ID: NCT00918723

High Throughput Drug Sensitivity Assay for Selecting Treatment for Relapsed/Refractory AML (8003)
Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

Investigator: Pamela Becker, MD, PhD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01872819

IAP for Induction of Newly Diagnosed Acute Myeloid Leukemia (2674)
Idarubicin, Cytarabine and Pravastatin (IAP) for Induction of Newly Diagnosed Acute Myeloid Leukemia (AML)

Investigator: Raya Mawad;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01831232

Safety Study of SGN-CD33A Acute Myeloid Leukemia (2690)
A Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia

Investigator: Roland Walter, MD;   Conditions: Acute Myeloid Leukemia (AML);    Status: Recruiting;   Study ID: NCT01902329

TREC for Relapsed or Refractory Lymphoid Malignancies (PSOC 2502)
A Phase I Trial of Bendamustine/Treanda, Rituxmab, Etoposide, and Carboplatin (TREC) for Patients With Relapsed or Refractory Lymphoid Malignancies

Investigator: Ajay K. Gopal, MD;   Conditions: Lymphoma;    Status: Recruiting;   Study ID: NCT01165112

Adoptive Immunotherapy for Relapsed AML, MDS, or CML (FH 2498)
Phase I/II Study of Adoptive Immunotherapy After Allogeneic HCT With Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-specific T Cell Receptor for Patients With High Risk or Relapsed AML, MDS, or CML

Investigator: Merav Bar, MD;   Conditions: Acute Myeloid Leukemia (AML); Bone Marrow and Hematopoietic Stem Cell Transplant (BMT and HSCT); Leukemia;    Status: Recruiting;   Study ID: NCT01640301

Cord Blood Cell Infusion Post Chemotherapy for AML (2584)
Pilot Study Evaluating the Use of Ex Vivo Expanded Cord Blood Progenitors as Supportive Care Following Induction Chemotherapy (FLAG) in Patients with Relapsed/Refractory AML

Investigator: Colleen Delaney, MD, MSc;   Conditions: Acute Myeloid Leukemia (AML); Hematologic Malignancies; Leukemia;    Status: Recruiting;   Study ID: NCT01701323

Tosedostat with Cytarabine or Decitabine for AML
A Phase II Study of Tosedostat in Combination With Either Cytarabine or Decitabine in Newly Diagnosed AML or High-Risk MDS

Investigator: John M. Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01567059

CSL362 for CD123+ Acute Myeloid Leukemia Currently in Remission
A Phase 1 Study of CSL362 (Anti-IL3Ra / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission with Incomplete Platelet Recovery at High Risk for Early Relapse

Investigator: Roland Walter, MD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01632852

Quizartinib for Relapsed or Refractory Acute Myeloid Leukemia (2623)
A Phase 2, Randomized, Open-label study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Investigator: John Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01565668

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (2645)
A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Investigator: Vivian Oehler, MD;   Conditions: Chronic Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01650805

Marqibo® for Older Patients w/ Newly Diagnosed ALL (20112071)
A Phase 3, Multicenter, Randomized Study to Evaluate the Substitution of Marqibo® (Vincristine Sulfate Liposomes Injection, VSLI) for Standard Vincristine Sulfate Injection (VSI) in the Induction, Intensification, and Maintenance Phases of Combination Chemotherapy in the Treatment of Subjects = 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Investigator: Andrei Shustov, MD;   Conditions: Acute Lymphoid Leukemia;    Status: Recruiting;   Study ID: NCT01439347

Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients (2572)
A Phase I/II Study of Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients with Untreated Acute Myeloid Leukemia

Investigator: John Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia (AML);    Status: Recruiting;   Study ID: NCT01756677

Decitabine + Mitoxantrone Hydrochloride, Etoposide, and Cytarabine for AML or MDS (2652)
Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase I/II Study

Investigator: Roland Walter, MD;   Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes;    Status: Recruiting;   Study ID: NCT01729845

PLX3397 for Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1/2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Investigator: John M. Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01349049

Bortezomib for High-Risk Acute Myeloid Leukemia in Remission
A Phase II Study of Subcutaneous Bortezomib as Maintenance Therapy for Patients With High-risk Acute Myeloid Leukemia in Remission

Investigator: John M. Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01465386

Radioimmunotherapy + SCT for Advanced AML, ALL, or MDS
Hematopoietic Cell Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate

Investigator: John M. Pagel, MD;   Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome;    Status: Recruiting;   Study ID: NCT00988715

GA101 (RO5072759) for Previously Untreated Chronic Lymphocytic Leukemia (2514)
An Open-Label, Multicenter, Phase Ib Trial of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Investigator: Ajay K. Gopal, MD;   Conditions: Chronic Lymphocytic Leukemia;    Status: Closed;   Study ID: NCT01300247

Combination Chemotherapy for Young Patients with ALL (COG AALL0331)
COG - Standard Risk B-Precursor Acute Lymphoblastic Leukemia: A Phase III Group Wide Study

Investigator: Blythe Thomson, MD;   Conditions: Acute Lymphoid Leukemia (ALL);    Status: Closed;   Study ID: NCT00103285

Decitabine Followed by Idarubicin and Cytarabine for AML or MDS
Phase II Trial Examining Epigenetic Priming With Decitabine Followed by Idarubicin and Cytarabine for Patients With Relapsed or Refractory AML

Investigator: Derek L. Stirewalt, MD;   Conditions: Leukemia, Myelodysplastic Syndromes;    Status: Recruiting;   Study ID: NCT01607645

Umbilical Cord Blood Transplant w/wo Ex-Vivo Expanded Cord Blood Progenitor Cells
Multi-center, Open-label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation With or Without Infusion of Off-the-shelf ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients With Hematologic Malignancies

Investigator: Colleen Delaney, MD;   Conditions: Leukemia;    Status: Pending;   Study ID: NCT01690520

Outpatient Induction Chemotherapy for Newly Diagnosed AML or MDS (7910)
Feasibility of Outpatient Induction Chemotherapy for Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Investigator: Pamela S. Becker, MD, PhD;   Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome;    Status: Recruiting;   Study ID: NCT01807091

Liposomal Cytarabine-Daunorubicin CPX-351 for Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (2642)
Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults With Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality

Investigator: Roland B. Walter, MD;   Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome;    Status: Recruiting;   Study ID: NCT01804101

Oral Azacitidine for MDS, CMML and AML (2474)
A Phase I, Open-Label, Dose-Escalation Study to Evaluate The Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).

Investigator: Bart Scott, MD;   Conditions: Myelodysplastic Syndromes (MDS);, Chronic Myelomonocytic Leukemia (CMML);, Acute Myelogenous Leukemia (AML);    Status: Closed;   Study ID: NCT00528983

CWP232291 for Relapsed or Refractory AML (2513)
A Phase I Clinical Study of CWP232291 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Investigator: John Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia (AML);    Status: Closed;   Study ID: NCT01398462

PF-04449913 for Hematologic Malignancies (UW09021)
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies

Investigator: Vivian Oehler, M.D,;   Conditions: Hematologic Malignancies;    Status: Closed;   Study ID: NCT00953758

Oral MEK inhibitor for Relapsed/Refractory Leukemias (2344)
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias

Investigator: Roland B. Walter, MD;   Conditions: Relapsed or Refractory Leukemia;    Status: Closed;   Study ID: NCT00920140

Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML) (09048)
Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With FLT3-ITD Activating Mutations

Investigator: Elihu Estey, MD;   Conditions: Acute Myeloid Leukemia;    Status: Closed;   Study ID: NCT00989261

Clofarabine, Cytarabine, and G-CSF for Newly Diagnosed Acute Myeloid Leukemia or Advanced MDS (7144)
Phase 2 Study Of Clofarabine With High Dose Cytarabine And G-CSF Priming In Adult Patients Under Age 60 With Newly Diagnosed Acute Myeloid Leukemia Or Advanced Myelodysplastic Syndrome

Investigator: Pamela Becker, MD, PhD;   Conditions: Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS);    Status: Closed;   Study ID: NCT01101880

Bendamustine Hydrochloride and Idarubicin for Previously Untreated AML or MDS (2413)
Safety and Clinical Activity of TreandaTM (Bendamustine HCL) and Idarubicin in Combination Therapy for Patients Over Age 60 with Previously Untreated Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (MDS)

Investigator: John M. Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia (AML); Hematologic Malignancies; Leukemia;    Status: Closed;   Study ID: NCT01141725

GSK2130579A for Acute Myeloid Leukemia (AML) (WT1-AS01B-AML-001)
Study of GSK2130579A Tumor-Antigen-Specific Cancer Immunotherapeutic as Post-consolidation Therapy in Adult Patients in First Complete Remission

Investigator: Elihu Estey, MD;   Conditions: WT1-positive Acute Myeloid Leukemia;    Status: Closed;   Study ID: NCT00725283

Inotuzumab Ozogamicin for Relapsed Or Refractory Acute Lymphoblastic Leukemia
An Open-Label, Randomized Phase 3 Study Of Inotuzumab Ozogamicin Compared To A Defined Investigator's Choice In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)

Investigator: Dr. Ryan Cassaday;   Conditions: Acute Lymphoblastic Leukemia;    Status: Recruiting;   Study ID: NCT01564784